The IBIS-II DCIS and NSABP B-35 trials (Table 2) compared the effect of anastrozole (a non-steroidal aromatase inhibitor) with that of tamoxifen in hormone receptor-positive postmenopausal DCIS patients.337,338 They found that anastrozole could be a comparable surrogate for tamoxifen, as it showed a significant improvement in the breast cancer-free interval in postmenopausal population who were younger than 60 years. The gene discussed is CYP19A1; the disease is breast cancer.